<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395252</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT-No. 2005-005168-94</org_study_id>
    <nct_id>NCT00395252</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer</brief_title>
  <acronym>ATIP</acronym>
  <official_title>Multicenter Phase II-trial to Investigate Safety and Efficacy of an Adjuvant Therapy With Gemcitabine and Erbitux® in Patients With R0 or R1 Resected Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmen Schade-Brittinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized Phase II study to evaluate immunochemotherapy in
      patients with R0 OR R1-resected pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Available study data indicated a possible benefit from adjuvant chemotherapy for patients
      with resected pancreatic cancer. The optimal therapy regimen has yet to be determined.

      Based on the experiences with cetuximab (Erbitux®)and gemcitabine in advanced pancreatic
      cancer and with gemcitabine as adjuvant therapy, the aim of this study was to evaluate the
      feasibility of the combined treatment of cetuximab and gemcitabine in patients with R0 or
      R1-resectable pancreatic cancer and to evaluate if the disease free survival can be increased
      by the addition of an EGFR-targeted therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>18 months after registration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>n.a</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>n.a</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>19 months since registration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>one arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab (Erbitux®) and Gemcitabine</intervention_name>
    <description>Cetuximab:
Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)
Gemcitabine:
1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered
Mode of administration:
Intravenous infusion</description>
    <arm_group_label>one arm study</arm_group_label>
    <other_name>Cetuximab</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provided signed written informed consent.

          -  Men and woman age &gt; 18 years

          -  Histologically confirmed R0 OR R1 resected ductal adenocarcinoma of the pancreas

          -  Life expectancy &gt;12 weeks

          -  Patients with performance status of ECOG ≤ 2

          -  Patients without metastasis

        Exclusion Criteria:

          -  Women of child bearing potential (WOCP) who are unwilling or unable to use an
             acceptable method to avoid pregnancy for the entire study period and follow-up to 4
             weeks after the study.

          -  Women who are pregnant or breastfeeding.

          -  Women with a positive pregnancy test on enrollment or prior to study drug
             administration.

          -  Dementia, altered mental status, or any psychiatric condition that would prohibit the
             understanding or rendering of informed consent.

          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of
             the cervix. (Patients with a previous malignancy but without evidence of disease for &gt;
             5 years will be allowed to enter the trial).

          -  Inadequate hematologic function defined by an absolute neutrophils count (ANC) &lt;
             1,500/mm³, a platelet count &lt; 100,000/mm³ and a hemoglobin &lt; 9 g/dL.

          -  Inadequate hepatic function defined by the upper limit of normal (ULN), AST and ALT
             levels &gt; 5 times the ULN.

          -  Serum bilirubin &gt; 1.5 times the ULN.

          -  Inadequate renal function defined by a serum creatinine &gt; 1.5 times the ULN.

          -  Prior cetuximab or other therapy that targets the EGF pathway.

          -  Prior antibody therapy.

          -  Any known allergic reaction against cetuximab.

          -  Any concurrent chronic systemic immune therapy, radiation therapy, hormonal therapy
             (except for physiological replacement), or any other investigational agents.

          -  HIV infection.

          -  Having participated in another clinical trial in the preceding 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Gress, Prof.Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Gastroenterologie, Endokrinologie und Stoffwechsel, University of Marburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Interdisziplinäres Tumorzentrum (Comprehensive Cancer Center)</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin II, Klinikum der Universität Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemein-, Viszeral- und Thoraxchirurgie, Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt. für Chirurgie, Universitätsklinikum Mannheim gGmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Giessen und Marburg, Standort Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU München</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik- und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Fensterer H, Schade-Brittinger C, Müller HH, Tebbe S, Fass J, Lindig U, Settmacher U, Schmidt WE, Märten A, Ebert MP, Kornmann M, Hofheinz R, Endlicher E, Brendel C, Barth PJ, Bartsch DK, Michl P, Gress TM; Arbeitsgemeinschaft Internistische Onkologie. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013 Oct;24(10):2576-81. doi: 10.1093/annonc/mdt270. Epub 2013 Jul 29.</citation>
    <PMID>23897705</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2006</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Philipps University Marburg Medical Center</investigator_affiliation>
    <investigator_full_name>Carmen Schade-Brittinger</investigator_full_name>
    <investigator_title>Philipps University</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>phase 2</keyword>
  <keyword>R0 or R1 resected Adenocarcinoma of the Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

